Skip to main content
. Author manuscript; available in PMC: 2021 Apr 21.
Published in final edited form as: N Engl J Med. 2018 Nov 1;379(18):1711–1721. doi: 10.1056/NEJMoa1807315

Figure 1. Adverse Events Due to Hu5F9-G4 (5F9), Rituximab, or Both and On-Target Anemia Effect of 5F9.

Figure 1.

Panel A shows the adverse events that occurred in at least 10% of the patients during treatment. Panel B shows the levels of hemoglobin and reticulocytes over time in a representative patient (with diffuse large B-cell lymphoma) during the study. The priming dose of 1 mg of 5F9 per kilogram of body weight was received on day 1 (green arrow). The patient received maintenance doses of 30 mg of 5F9 per kilogram (blue arrows).

HHS Vulnerability Disclosure